Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pulmonx CorpLUNG · Entity 2359 | Chief Commercial Officer | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pulmonx Corp
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 449,832 |
Ending reported balance
After 2026-09-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-09-01 · Sale · Disposed 2,213 · Balance 455,498 F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 2, 2026. Row 2 · 2026-09-01 · Sale · Disposed 2,390 · Balance 453,108 F2: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025. Row 3 · 2026-09-01 · Sale · Disposed 1,530 · Balance 451,578 F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024. Row 4 · 2026-09-01 · Sale · Disposed 1,746 · Balance 449,832 F4: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 2, 2026.
F2: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.
F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
F4: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2021 Filed May 25, 2021 21:18 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 24 | $41.49 | $995.76 |
DisclosureSEC source: 0001209191-21-035741 · doc4.xml · nonDerivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,695 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. Read SEC document |
| May 24, 2021 Filed May 25, 2021 21:18 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,363 | $40.81 | $178,054.03 |
DisclosureSEC source: 0001209191-21-035741 · doc4.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,719 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.42 to $41.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 1,981 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on May 24, 2021. Read SEC document |
| May 18, 2021 Filed May 19, 2021 21:19 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 49,428 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001209191-21-034061 · doc4.xml · derivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,428 shares Expires 2025-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| May 18, 2021 Filed May 19, 2021 21:19 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionCommon Stock | 49,428 | $1.40 | $69,199.20 |
DisclosureSEC source: 0001209191-21-034061 · doc4.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 11, 2021 22:58 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1 | $42.51 | $42.51 |
DisclosureSEC source: 0001209191-21-031854 · doc4.xml · nonDerivative · entry 4 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,673 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. Read SEC document |
| May 10, 2021 Filed May 11, 2021 22:58 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 118 | $42.25 | $4,985.50 |
DisclosureSEC source: 0001209191-21-031854 · doc4.xml · nonDerivative · entry 3 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,674 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. Read SEC document |
| May 10, 2021 Filed May 11, 2021 22:58 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 900 | $41.47 | $37,323.00 |
DisclosureSEC source: 0001209191-21-031854 · doc4.xml · nonDerivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,792 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.02 to $41.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 10, 2021 Filed May 11, 2021 22:58 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 3,778 | $40.47 | $152,895.66 |
DisclosureSEC source: 0001209191-21-031854 · doc4.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,692 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 21:26 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,797 | $43.24 | $207,422.28 |
DisclosureSEC source: 0001209191-21-027833 · doc4.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,470 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.83 to $43.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 23:41 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 266 | $48.46 | $12,890.36 |
DisclosureSEC source: 0001209191-21-025748 · doc4.xml · nonDerivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,064 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.11 to $48.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 23:41 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,531 | $47.59 | $215,630.29 |
DisclosureSEC source: 0001209191-21-025748 · doc4.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,330 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.08 to $48.045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 8, 2021 01:05 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 319 | $48.43 | $15,449.17 |
DisclosureSEC source: 0001209191-21-025997 · doc4a.xml · nonDerivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,267 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.09 to $48.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 8, 2021 01:05 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,478 | $47.59 | $213,108.02 |
DisclosureSEC source: 0001209191-21-025997 · doc4a.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,586 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.08 to $48.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 10, 2020 Filed Apr 8, 2021 22:11 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001209191-21-026141 · doc5.xml · derivative · entry 2 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,428 Underlying: Common Stock · 22,000 shares Expires 2025-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| December 10, 2020 Filed Apr 8, 2021 22:11 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionCommon Stock | 22,000 | $1.40 | $30,800.00 |
DisclosureSEC source: 0001209191-21-026141 · doc5.xml · nonDerivative · entry 1 Rose Geoffrey Beran · CIK 0001804146 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.